A Randomized Open-label Phase II Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Ralimetinib (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 10 Apr 2017 Planned End Date changed from 1 Jun 2020 to 1 Apr 2018.
- 10 Apr 2017 Status changed from recruiting to discontinued.